Transformation by v-ErbB is correlated with the expression of both tissue-specific and transformation-specific phosphorylation events. Moreover, recent evidence suggests that there are qualitative differences between ligand-dependent vs. ligand-independent ErbB signalling pathways. On the basis of these studies, we propose that v-ErbB oncoproteins are not simply constitutively activated EGF-receptors, but rather that these mutant receptors are capable of sending unique and specifically oncogenic signals. In this regard, we have identified a novel, transformation-associated complex of tyrosine phosphoproteins in v-ErbB transformed fibroblasts. This complex is composed of the signal adapter proteins Shc and Grb2, the guanine nucleotide exchange factor Sos, a novel tyrosine phosphorylated form of the cytoskeletal regulatory protein caldesmon, as well as two novel tyrosine phosphorylated proteins (i.e., pp75 and pp72) with no known homologues based on primary sequence information. In this application we propose to focus much of our effort on a careful dissection of the functional role of this complex in v-ErbB-mediated fibroblast transformation. These studies will allow us to determine if components of this novel transformation-associated complex are required for v-ErbB mediated stress fiber disassembly and/or transformation. We believe this intensive analysis of v-ErbB-mediated oncogenic signalling is warranted, based on the extensive body of information available regarding the molecular basis of oncogenic activation of the avian receptor, the stringency of the biological tests to be used in these analyses (transformation of primary cells in culture, and tumorigenicity assays using an avian gene in avian tissues), and based on the premise that oncogenic (i.e., ligand-independent) ErbB1 signalling pathways may be qualitatively distinct from mitogenic (i.e., ligand-dependent) ErbB1 signalling pathways. The ErbB family of proto-oncogenes has been implicated in the etiology and progression of a variety of human malignancies, and the results of these studies may, therefore, have important implications for the diagnosis and treatment of certain human cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA079808-01A1
Application #
2906984
Study Section
Cellular Biology and Physiology Subcommittee 1 (CBY)
Program Officer
Freeman, Colette S
Project Start
1999-08-05
Project End
2004-05-31
Budget Start
1999-08-05
Budget End
2000-05-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Leslie, Kimberly K; Sill, Michael W; Fischer, Edgar et al. (2013) A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 129:486-94
Wilken, Jason A; Perez-Torres, Marianela; Nieves-Alicea, Rene et al. (2013) Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab. Biochemistry 52:4531-40
Wilken, Jason A; Badri, Tayf; Cross, Sarah et al. (2012) EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem 4:447-69
Wilken, Jason A; Baron, Andre T; Maihle, Nita J (2011) The epidermal growth factor receptor conundrum. Cancer 117:2358-60
Wilken, Jason A; Baron, Andre T; Foty, Ramsey A et al. (2011) Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and ?5-integrin. Biochemistry 50:4309-21
Wilken, Jason A; Maihle, Nita J (2010) Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci 1210:53-65
Peng, S; Maihle, N J; Huang, Y (2010) Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 29:2153-9
Albitar, Lina; Pickett, Gavin; Morgan, Marilee et al. (2010) EGFR isoforms and gene regulation in human endometrial cancer cells. Mol Cancer 9:166
Narayan, Murli; Wilken, Jason A; Harris, Lyndsay N et al. (2009) Trastuzumab-induced HER reprogramming in ""resistant"" breast carcinoma cells. Cancer Res 69:2191-4
Dogan, Soner; Hu, Xin; Zhang, Yan et al. (2007) Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice. Breast Cancer Res 9:R91

Showing the most recent 10 out of 27 publications